Baxalta Ventures
VC Fund
Cambridge, United States
Baxalta Ventures is a VC fund in Cambridge focused on Medical and Biotechnology. Baxalta Ventures invests globally in healthcare companies developing novel products and therapies consistent with Baxalta’s commitment to strive for excellence on behalf of patients, caregivers and healthcare providers. The Baxalta Ventures team brings unique expertise in products and therapies across the pharmaceuticals, medical devices, andbiotechnology sectors. As part of Baxalta, they have access to additional expertise in product research, development, manufacturing, and commercialization to their work with entrepreneurs.Baxalta Ventures believe that establishing strong relationships with entrepreneurs, other venture capital investors, and industry experts is critical for the long-term success of their portfolio companies. They aim to accelerate and enhance commercialization activities in portfolio companies by creating strategic alliances with other venture capital funds and by leveraging Baxalta’s expertise in clinical development, production, and marketing of therapeutic solutions. Baxalta Ventures is managed by an experienced leadership team with extensive expertise in venture capital, scientific innovation, and operational leadership in the healthcare industry. Their initial investments are generally up to $5 million and may increase throughout the life of the company.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Baxalta Ventures invests in
Stages Baxalta Ventures invests in
Countries Baxalta Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Geeta Vemuri
|
|||
Marta New
|
|||
Investment Focus
Industry
- Medical 2 (40%)
- Biotechnology 2 (40%)
- Health Care 1 (20%)
- Therapeutics 1 (20%)
- Pharmaceutical 1 (20%)
Stage
- Series A 2 (40%)
- Series B 1 (20%)
Country
- United States 1 (20%)
- The Netherlands 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Geeta Vemuri
Managing Partner, Baxalta Ventures
|
Managing Partner, Baxalta Ventures | Total investments: 13 | Find email | |
|
Marta New
Principal
|
Principal | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Syntimmune
|
Syntimmune is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. It is seeking advancing novel therapies based on its expertise in the biology of the neonatal Fc receptor (FcRn) and its role in the pathogenesis of IgG-mediated autoimmune diseases. Laurence and Richard Blumbergfounded Syntimmune in 2013. Its headquarters is in Boston in Massachusetts. | $50M / Series B / Jun 21, 2017 | |
|
Syntimmune
|
Syntimmune is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. It is seeking advancing novel therapies based on its expertise in the biology of the neonatal Fc receptor (FcRn) and its role in the pathogenesis of IgG-mediated autoimmune diseases. Laurence and Richard Blumbergfounded Syntimmune in 2013. Its headquarters is in Boston in Massachusetts. | $8M / Series A / Nov 17, 2016 | |
Gadeta
|
Gadeta is a research and development company that develops immunotherapies for cancer. It has developed a technology platform based on combinatorial T Cell receptor exchange (CTE) to create optimized gamma delta (γδ) T-cell receptors (TCRs) with enhanced anti-cancer reactivity. Gadeta’s new cell-based anti-cancer product called T Cells EngineeredTo Express A Defined Gamma Delta TCR (TEGs) has strong therapeutic potential for combating and eradicating both hematological and solid tumors. This approach utilizes high-affinity γδ TCRs expressed on αβ T cells with superior proliferation capacity. | $7.1M / Series A / Mar 29, 2016 | |
|
Syntimmune
|
Syntimmune is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. It is seeking advancing novel therapies based on its expertise in the biology of the neonatal Fc receptor (FcRn) and its role in the pathogenesis of IgG-mediated autoimmune diseases. Laurence and Richard Blumbergfounded Syntimmune in 2013. Its headquarters is in Boston in Massachusetts. | $10M / Series A / Mar 22, 2016 | |
|
Syntimmune
|
Syntimmune is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. It is seeking advancing novel therapies based on its expertise in the biology of the neonatal Fc receptor (FcRn) and its role in the pathogenesis of IgG-mediated autoimmune diseases. Laurence and Richard Blumbergfounded Syntimmune in 2013. Its headquarters is in Boston in Massachusetts. | $8M / Series A / Oct 24, 2014 |
Co-Investors
Apple Tree Partners
4 deals together
Partners Innovation Fund
4 deals together
Medicxi
1 deal together
Utrecht Holdings
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Baxalta Ventures invest in?
Baxalta Ventures invests primarily in Medical, Biotechnology and Health Care startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Baxalta Ventures?
Public channels for Baxalta Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Baxalta Ventures?
The team at Baxalta Ventures includes Geeta Vemuri (Managing Partner, Baxalta Ventures) and Marta New (Principal). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
